ALUR
Allurion Technologies Inc.1.5400
+0.0200+1.32%
Dec 16, 4:00:02 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
18.88MP/E (TTM)
-Basic EPS (TTM)
-16.20Dividend Yield
0%Recent Filings
8-K
NYSE delisting initiated, appeal filed
Allurion Technologies' common stock and warrants were suspended from NYSE trading after market close on March 6, 2026, due to average global market cap below $15 million over 30 days, triggering delisting proceedings under Rule 802.01B. The company appealed and now trades on OTCID Market under ALUR/ALUR.WS while executing a plan—sparked by February 20 FDA approval of its Gastric Balloon System with Smart Capsule—to regain compliance or list on NYSE American. No impact on operations. Appeal success uncertain.
8-K
NYSE delisting notice issued
8-K
Warrant inducement yields $3M
Allurion Technologies induced holders of existing warrants to exercise 2,659,565 shares at a reduced $1.15 price, netting ~$3.0 million gross proceeds. In exchange, it issued new warrants for 5,319,130 shares at $1.15, exercisable post-stockholder approval by June 30, 2026, with 4.99% ownership caps. Cash bolsters liquidity, but dilution awaits vote. Smart cash grab.
8-K
FDA approves Allurion balloon
Allurion Technologies scored FDA PMA approval on February 23, 2026, for its Gastric Balloon System with Smart Capsule, targeting adults aged 22-65 with BMI 30-40 kg/m² after failed weight loss attempts. The swallowable balloon resides four months, offering a no-surgery alternative to GLP-1s and bariatric procedures for ~80 million eligible Americans. FDA approval secured. Commercialization faces financing risks.
8-K
Preliminary Q4 revenue jumps
Allurion Technologies issued preliminary Q4 2025 results on January 12, 2026, projecting revenue of $3.3M-$3.7M—up 22%-37% quarter-over-quarter—while full-year revenue hit ~$15M. Operating expenses and losses improved substantially versus prior periods, fueled by a sharpened commercial strategy post-2025 pivot. Losses are shrinking. Management eyes FDA approval for its Smart Capsule ahead.
AEMD
Aethlon Medical, Inc.
2.94-0.11
AIRS
AirSculpt Technologies, Inc.
2.57-0.06
ALNT
Allient Inc.
54.64-0.39
ALRTF
ALR Technologies SG LTD.
0.02-0.00
MDT
Medtronic plc.
97.72-0.85
MGRM
Monogram Technologies Inc.
6.00+0.00
NVCR
NovoCure Limited
12.93-0.04
NXL
Nexalin Technology, Inc.
0.81-0.01
RBOT
Vicarious Surgical Inc.
2.43-0.04
TCRT
Alaunos Therapeutics, Inc.
4.36+0.09